What, in your view, are the indications and clinical phenotypes with MAC lung disease in which the FDA-approved amikacin liposome inhalation suspension is most like to achieve microbial conversion and improve clinical outcomes?
What, in your view, are the indications and clinical phenotypes with MAC lung disease in which the FDA-approved amikacin liposome inhalation suspension is most like to achieve microbial conversion and improve clinical outcomes?
Created by
Presenter
Director of University of Miami and VA Sarcoidosis Programs
Co-Director UM NTM Program
IRB Vice-Chairman, Miami VA Healthcare System
Assistant Professor of Department of Medicine
Assistant Professor of Clinical Public Health Sciences
Division of Pulmonary